Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 7, 2013 - Issue 6
Submit an article Journal homepage
333
Views
7
CrossRef citations to date
0
Altmetric
Reviews

Inhaled corticosteroids for asthma: on-demand or continuous use

Neil C ThomsonInstitute of Infection, Immunity & Inflammation, University of Glasgow and Respiratory Medicine, Gartnavel General Hospital, Glasgow, G12 OYN, UKCorrespondence[email protected]
&
Mark SpearsInstitute of Infection, Immunity & Inflammation, University of Glasgow and Respiratory Medicine, Gartnavel General Hospital, Glasgow, G12 OYN, UK
Pages 687-699 | Published online: 09 Jan 2014

References

  • Raherison C, Janson C, Jarvis D et al. Evolution of Asthma Severity in a Cohort of Young Adults: Is There Any Gender Difference? PLoS ONE 4(9), e7146 (2009).
  • O'Byrne P, Barnes P, Rodriquez-Roisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma the OPTIMA randomized trial. Am. J. Respir. Crit. Care Med. 164(8), 1392–1397 (2001).
  • Pauwels R, Pedersen S, Busse W et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 361, 1071–1076 (2003).
  • Williams LK, Peterson EL, Wells K et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J. Allergy Clin. Immunol. 128(6), 1185–1191 (2011).
  • Partridge M, van der Molen T, Myrseth S-E, Busse W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm. Med. 6(1), 13 (2006).
  • Busse WW, Pedersen S, Pauwels RA, Tan WC, Chen Y-Z, Lamm CJ, et al. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J. Allergy Clin. Immunol. 121(5), 1167–1174 (2008).
  • Fabbri LM. Does mild persistent asthma require regular treatment? N. Engl J. Med. 352(15), 1589–1591 (2005).
  • Barnes PJ. Glucocorticosteroids: current and future directions. Br. J. Pharmol. 163(1), 29–43 (2011).
  • Clark AR, Belvisi MG. Maps and legends: The quest for dissociated ligands of the glucocorticoid receptor. Pharmacol. Ther. 134(1), 54–67 (2012).
  • Vandevyver S, Dejager L, Tuckermann J, Libert C. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology 154(3), 993–1007 (2013).
  • Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma: An evidence-based evaluation. Chest 130(5), 1301–1311 (2006).
  • Profita M, Gagliardo R, Di Giorgi R et al. Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy 60(3), 323–329 (2005).
  • Nie M, Knox AJ, Pang L. β2-Adrenoceptor Agonists, Like Glucocorticoids, Repress Eotaxin Gene Transcription by Selective Inhibition of Histone H4 Acetylation. J. Immunol. 175(1), 478–486 (2005).
  • Descalzi D, Folli C, Nicolini G et al. Anti-proliferative and anti-remodelling effect of beclomethasone dipropionate, formoterol and salbutamol alone or in combination in primary human bronchial fibroblasts. Allergy 63(4), 432–437 (2008).
  • Usmani OS, Ito K, Maneechotesuwan K et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am. J. Respir. Crit. Care Med. 172(6), 704–712 (2005).
  • Raissy HH, Kelly HW, Harkins M, Szefler SJ. Inhaled corticosteroids in lung diseases. Am. J. Respir. Crit. Care Med. 187(8), 798–803 (2013).
  • Rossi GA, Cerasoli F, Cazzola M. Safety of inhaled corticosteroids: Room for improvement. Pulm. Pharmacol. Ther. 20(1), 23–35 (2007).
  • Gulliver T, Morton R, Eid N. Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. Paediatr. Drugs 9(3), 185–194 (2007).
  • Gentile DA, Skoner DP. New asthma drugs: small molecule inhaled corticosteroids. Curr. Opin. Pharmacol. 10(3), 260–265 (2010).
  • Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J. 28(5), 104210–50 (2006).
  • Hirst PH, Bacon RE, Pitcairn GR, Silvasti M, Newman SP. A comparison of the lung deposition of budesonide from Easyhaler®, Turbuhaler® and pMDI plus spacer in asthmatic patients. Respir. Med. 95(9), 720–727 (2001).
  • Leach CL, Kuehl PJ, Chand R, Ketai L, Norenberg JP, McDonald JD. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann. Allergy Asthma Immunol. 108(3), 195–200 (2012).
  • Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids, Does it matter? J. Allergy Clin. Immunol. 124(6 Suppl. 1), S88–S93 (2009).
  • Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur. Respir. J. 10, 292–300 (1997).
  • Bergeron C, Hauber HP, Gotfried M et al. Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: Effect of hydrofluoroalkane-flunisolide. J. Allergy Clin. Immunol. 116(5), 983–989 (2005).
  • van den Berge M, ten Hacken NHT, Cohen J, Douma WR, Postma DS. Small airway disease in asthma and COPD: clinical implications. Chest 139(2), 412–23 (2011).
  • van den Berge M, ten Hacken NHT, van der Wiel E, Postma DS. Treatment of the bronchial tree from beginning to end: targeting small airway inflammation in asthma. Allergy 68(1), 16–26 (2013).
  • Lipworth B. Targeting the small airways asthma phenotype: if we can reach it, should we treat it? Ann. Allergy Asthma Immunol. 110(4), 233–239 (2013).
  • Farah CS, King GG, Brown NJ, Peters MJ, Berend N, Salome CM. Ventilation heterogeneity predicts asthma control in adults following inhaled corticosteroid dose titration. J. Allergy Clin. Immunol. 130(1), 61–68 (2012).
  • van der Wiel E, ten Hacken NHT, Postma DS, van den Berge M. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: A systematic review. J. Allergy Clin. Immunol. 131(3), 646–657 (2013).
  • Scichilone N, Battaglia S, Taormina S, Modica V, Pozzecco E, Bellia V. Alveolar nitric oxide and asthma control in mild untreated asthma. J. Allergy Clin. Immunol. 131(6), 1513–1517 (2013).
  • Usmani OS, Barnes PJ. Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann. Med. 44(2), 146–156 (2012).
  • Colice G, Martin RJ, Israel E et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. J. Allergy Clin. Immunol. 132(1), 45–54 (2013).
  • Anderson WJ, Zajda E, Lipworth BJ. Are we overlooking persistent small airways dysfunction in community-managed asthma? Ann. Allergy Asthma Immunol. 109(3), 185–189.e2 (2012).
  • Price D, Martin RJ, Barnes N et al. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: A real-world observational study. J. Allergy Clin. Immunol. 126(3), 511–518.e10 (2010).
  • Price D, Thomas M, Haughney J et al. Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma. Respir. Med. (0) 2013.
  • Lasserson T, Cates C, Lasserson E, White J. Fluticasone versus ‘extrafine’ HFA-beclomethasone dipropionate for chronic asthma in adults and children. Cochrane Database Syst. Rev. (2), CD005309 (2006).
  • Masoli M, Holt S, Weatherall M, Beasley R. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur. Respir. J. 23(4), 552–558 (2004).
  • Adams N, Bestall J, Jones P. Inhaled budesonide at different doses for chronic asthma. Cochrane Database Syst. Rev. (2), CD003271 (2000).
  • Masoli M, Weatherall M, Holt S, Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax 59(1), 16–20 (2004).
  • Adams N, Bestall J, Jones P. Inhaled beclomethasone at different doses for chronic asthma. Cochrane Database Syst. Rev. (4), CD002879 (1999).
  • Powell H, Gibson PG. Initial starting dose of inhaled corticosteroids in adults with asthma: a systematic review. Thorax 59(12), 1041–1045 (2004).
  • Adams N, Bestall J, Jones P. Inhaled fluticasone at different doses for chronic asthma. Cochrane Database Syst. Rev. (4), CD003534 (2008).
  • Zhang L, Axelsson I, Chung M, Lau J. Dose response of inhaled corticosteroids in children with persistent asthma: a systematic review. Pediatrics 127(1), 129–138 (2011).
  • Derom E, Pauwels R. Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. Clin. Pharmacokinet. 44(8), 815–836 (2005).
  • Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch. Intern. Med. 159(9), 941–955 (1999).
  • Masoli M, Weatherall M, Holt S, Shirtcliffe P, Beasley R. Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis. Eur. Respir. J. 28(5), 960–967 (2006).
  • Lapi F, Kezouh A, Suissa S, Ernst P. The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur. Respir. J. 42(1), 79–86 (2013).
  • Sharek P, Bergman D, Ducharme F. Beclomethasone for asthma in children: effects on linear growth. Cochrane Database Syst. Rev.(3), CD001282 (1999).
  • Kelly HW, Sternberg AL, Lescher R et al. Effect of inhaled glucocorticoids in childhood on adult height. N. Engl J. Med. 367(10), 904–912 (2012).
  • Weatherall M, James K, Clay J et al. Dose–response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin. Exp. Allergy 38(9), 1451–148 (2008).
  • Harrison LI, Colice GL, Donnell D, Soria I, Dockhorn R. adrenal effects and pharmacokinetics of CFC-free beclomethasone dipropionate: a 14-day dose-response study. J. Pharm. Pharmacol. 51(3), 263–269 (1999).
  • Wolthers OD, Sergio F. Systemic activity of inhaled beclomethasone dipropionate: a double-blind comparison of volume spacers. Acta Paediatr. 101(2), 159–163 (2012).
  • Acerbi D, Brambilla G, Kottakis I. Advances in asthma and COPD management: Delivering CFC-free inhaled therapy using Modulite® technology. Pulm. Pharmacol. Ther. 20(3), 290–303 (2007).
  • Spears M, Thomson NC. Factors influencing individual variability to the therapeutic response to corticosteroids. Curr. Resp. Med. Rev. 2, 197–209 (2006).
  • Sloan CD, Gebretsadik T, Wu P, Mitchel EF, Hartert TV. Reactive versus proactive patterns of inhaled corticosteroid use. Ann. Am. Thor. Soc. 10(2), 131–134 (2013).
  • Sawicki G, Allen JL. Claim-based analyses of inhaled corticosteroid refill rates for asthma: who's kidding whom? Ann. Am. Thor. Soc. 10(2), 149–150 (2013).
  • Leach C, Davidson P, Hasselquist B, Boudreau R. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J. Aerosol. Med. 18(4), 379–385 (2005).
  • Pavord ID. Complex airway disease: an approach to assessment and management. Lancet Respir. Med. 1(1), 84–90 (2013).
  • Thomson NC, Spears M. Asthma guidelines and smokers. Chest 141(2), 286–288 (2012).
  • Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DYM. Body mass and glucocorticoid response in asthma. Am. J. Respir. Crit. Care Med. 178(7), 682–687 (2008).
  • Tantisira KG, Damask A, Szefler SJ et al. Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus. Am. J. Respir. Crit. Care Med. 185(12), 1286–1291 (2012).
  • Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 131(3), 636–645 (2013).
  • Invernizzi G, Ruprecht A, De Marco C, Mazza R, Nicolini G, Boffi R. Inhaled steroid/tobacco smoke particle interactions: a new light on steroid resistance. Resp. Res. 10(1), 48 (2009).
  • Selroos O, Edsbäcker S, Hultquist C. Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation. J. Asthma 41(8), 771–790 (2004).
  • Adcock IM, Caramori G, Kirkham PA. Strategies for improving the efficacy and therapeutic ratio of glucocorticoids. Curr. Opin. Pharmacol. 12(3), 246–251 (2012).
  • Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst. Rev. (2), CD009611 (2013).
  • Boushey HA, Sorkness CA, King TS et al. Daily versus as-needed corticosteroids for mild persistent asthma. N. Engl J. Med. 352(15), 1519–1528 (2005).
  • Papi A, Canonica GW, Maestrelli P et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N. Engl J. Med. 356(20), 2040–2052 (2007).
  • Papi A, Nicolini G, Baraldi E et al. Regular vs prn nebulized treatment in wheeze preschool children. Allergy 64(10), 1463–1471 (2009).
  • Zeiger RS, Mauger D, Bacharier LB et al. Daily or intermittent budesonide in preschool children with recurrent wheezing. N. Engl J. Med. 365(21), 1990–2001 (2011).
  • Turpeinen M, Nikander K, Pelkonen AS et al. Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study). Arch. Dis. Child. 93(8), 654–659 (2008).
  • Martinez FD, Chinchilli VM, Morgan WJ et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet 377(9766), 650–657 (2011).
  • Rodrigo GJ, Castro-Rodriguez JA. Daily vs. intermittent inhaled corticosteroids for recurrent wheezing and mild persistent asthma: a systematic review with meta-analysis. Respir. Med. 107(8), 1133–1340 (2013).
  • Calhoun W, Ameredes BT, Icitovic N et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the basalt randomized controlled trial. JAMA 308(10), 987–997 (2012).
  • Turpeinen M, Pelkonen AS, Nikander K et al. Bone mineral density in children treated with daily or periodical inhaled budesonide: the helsinki early intervention childhood asthma study. Pediatr. Res. 68(2), 169–73 (2010).
  • Usmani OS, Barnes PJ. Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann. Med. 0(0), 1–11 (2011).
  • Lipworth BJ, Basu K, Donald HP et al. Tailored second-line therapy in asthmatic children with the Arg16 genotype. Clin. Sci. 124(8), 521–528 (2013).
  • Price D, Musgrave SD, Shepstone L et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N. Engl J. Med. 364(18), 1695–1707 (2011).
  • Thomson N, Chaudhuri R. Asthma in smokers: challenges and opportunities. Curr. Opin. Pulm. Med. 15, 39–45 (2009).
  • Price D, Popov TA, Bjermer L et al. Effect of montelukast for treatment of asthma in cigarette smokers. J. Allergy Clin. Immunol. 131(3), 763–771 (2013).
  • Cates C, Lasserson T. Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children. Cochrane Database Syst. Rev. (1), CD007085 (2009).
  • Papi A, Corradi M, Pigeon-Francisco C et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir. Med. 1(1), 23–31 (2013).
  • De Bosscher K, Haegeman G, Elewaut D. Targeting inflammation using selective glucocorticoid receptor modulators. Curr. Opin. Pharmacol. 10(4), 497–504 (2010).
  • Woodcock A, Acerbi D, Poli G. Modulite® technology: pharmacodynamic and pharmacokinetic implications. Respir. Med. 96, S9–S15 (2002).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.